CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.» Read More
Some of Wednesday's midday movers:
Dec 23- The U.S. Food and Drug Administration said on Monday it has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder. Patients with congenital Factor XIIIA-subunit deficiency do not make enough of the Factor XIII protein that is important for normal blood clotting, the FDA said.
Companies are making headlines before the bell Thursday.
AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.
LONDON, Dec 19- AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture for up to $4.1 billion in a deal that will help return the group to growth, sending its shares to an new high.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.
LONDON, Dec 16- A new battle is looming over access to antiviral medicines in developing countries- this time for treating hepatitis C- more than a decade after a global showdown over the price of AIDS drugs in Africa.
Some of Friday's midday movers:
*AstraZeneca shares gain 2.2 percent. Dec 13- A new type of diabetes drug from Bristol-Myers Squibb and AstraZeneca has been endorsed by U.S. medical experts, two years after it was rejected by regulators because of safety concerns.
Bristol-Myers Squibb is developing the drug, which is already approved in Europe, in partnership with AstraZeneca. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
Bristol-Myers is developing the drug, which is already approved in Europe, in partnership with AstraZeneca Plc. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
LONDON, Dec 12- Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries.
Dec 10- AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious liver disease.
Dec 6- U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus. Most patients will be treated with the $1,000- a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller.
*Two or 3 more deals and Compugen could turn a profit. TEL AVIV, Nov 25- Israel's Compugen, which is trying to develop commercial drugs using computer models, says it could turn a profit if it can secure two or three more deals like its recent partnership with Bayer in immuno-oncology.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
The "C" class has been teaching the rest of the market a lesson this year, leading the way with oversized gains.
Nov 18- AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. AbbVie shares rose 3 percent. Shares of Enanta Pharmaceuticals Inc, which collaborates with AbbVie on one of the drugs included in the treatment, rose 4 percent.
Does the jobs report suggest the economy is kicking back into gear? Find out in the week ahead.
Nov 7- Bristol-Myers Squibb Co said on Thursday that it would no longer conduct research to discover new drugs for hepatitis C, diabetes and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer.